|
|
Volumn 171, Issue 1, 2014, Pages 10-13
|
|
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: A critical appraisal
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
OMALIZUMAB;
PLACEBO;
ANTIALLERGIC AGENT;
ANTIIDIOTYPIC ANTIBODY;
MONOCLONAL ANTIBODY;
7 DAY URTICARIA ACTIVITY SCORE;
ADULT;
ANGIONEUROTIC EDEMA;
CHILD;
CHRONIC IDIOPATHIC URTICARIA;
CHRONIC URTICARIA;
CHRONIC URTICARIA QUALITY OF LIFE QUESTIONNAIRE;
CONTROLLED STUDY;
DERMATOLOGY LIFE QUALITY INDEX;
DISEASE SEVERITY;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG SAFETY;
EXTERNAL VALIDITY;
FOLLOW UP;
HUMAN;
IDIOPATHIC DISEASE;
INTENTION TO TREAT ANALYSIS;
MULTICENTER STUDY;
NOTE;
OUTCOME ASSESSMENT;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUESTIONNAIRE;
RANDOMIZED CONTROLLED TRIAL;
SCORING SYSTEM;
SLEEP;
SPONTANEOUS URTICARIA;
UNSPECIFIED SIDE EFFECT;
URTICARIA;
FEMALE;
MALE;
PRURITUS;
ANTI-ALLERGIC AGENTS;
ANTIBODIES, ANTI-IDIOTYPIC;
ANTIBODIES, MONOCLONAL, HUMANIZED;
FEMALE;
HUMANS;
MALE;
PRURITUS;
URTICARIA;
|
|
EID: 84904917958
PISSN: 00070963
EISSN: 13652133
Source Type: Journal
DOI: 10.1111/bjd.13073 Document Type: Note |
|
Times cited : (5)
|
|
References (3)
|
